Ocugen, Inc. (NASDAQ: OCGN) Featured in Virtual Coverage of the 32nd Annual ROTH Conference
Ocugen, Inc. (NASDAQ: OCGN) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. The company's Phase 3 small molecule drug candidate for oGVHD, if approved, will be the first and only treatment for this orphan disease. Ocugen's breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. For more information on the company,…